Stock soars as Viibryd approval positions Clinical Data as acquisition candidate
This article was originally published in Scrip
Executive Summary
Clinical Data investors 24 January were overjoyed about the US FDA's approval of the company's first-of-its-kind antidepressant Viibryd (vilazodone HCl) as a treatment for adults with major depressive disorder (MDD).